William Y. Go

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.7K citations · Full text

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson et al. · The Lancet Oncology · 2018 · 2.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Axicabtagene Ciloleucel +9

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.6K citations · Full text

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer

Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus et al. · Journal of Clinical Oncology · 2014 · 623 citations

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Molecular Therapy · 2017 · 601 citations · Full text